Petros Total Assets from 2010 to 2025
| PTPI Stock | USD 0.13 0.03 18.75% |
Total Assets | First Reported 2019-12-31 | Previous Quarter 10.6 M | Current Value 17.6 M | Quarterly Volatility 17.1 M |
Check Petros Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Petros Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.5 M, Interest Expense of 532.9 K or Selling General Administrative of 10.6 M, as well as many indicators such as Price To Sales Ratio of 14.69, Dividend Yield of 13.08 or Days Sales Outstanding of 28.22. Petros financial statements analysis is a perfect complement when working with Petros Pharmaceuticals Valuation or Volatility modules.
Petros | Total Assets | Build AI portfolio with Petros Stock |
Latest Petros Pharmaceuticals' Total Assets Growth Pattern
Below is the plot of the Total Assets of Petros Pharmaceuticals over the last few years. Total assets refers to the total amount of Petros Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Petros Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Petros Pharmaceuticals' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Petros Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 10.64 M | 10 Years Trend |
|
Total Assets |
| Timeline |
Petros Total Assets Regression Statistics
| Arithmetic Mean | 55,283,832 | |
| Geometric Mean | 48,263,418 | |
| Coefficient Of Variation | 37.94 | |
| Mean Deviation | 16,772,433 | |
| Median | 66,886,120 | |
| Standard Deviation | 20,974,674 | |
| Sample Variance | 439.9T | |
| Range | 59.8M | |
| R-Value | (0.76) | |
| Mean Square Error | 202.1T | |
| R-Squared | 0.57 | |
| Significance | 0.0007 | |
| Slope | (3,329,955) | |
| Total Sum of Squares | 6599.1T |
Petros Total Assets History
Other Fundumenentals of Petros Pharmaceuticals
Petros Pharmaceuticals Total Assets component correlations
Click cells to compare fundamentals
About Petros Pharmaceuticals Financial Statements
Investors use fundamental indicators, such as Petros Pharmaceuticals' Total Assets, to determine how well the company is positioned to perform in the future. Although Petros Pharmaceuticals' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Total Assets | 10.6 M | 10.1 M | |
| Intangibles To Total Assets | 0.30 | 0.50 |
Currently Active Assets on Macroaxis
When determining whether Petros Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Petros Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Petros Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Petros Pharmaceuticals Stock:Check out the analysis of Petros Pharmaceuticals Correlation against competitors. For more detail on how to invest in Petros Stock please use our How to Invest in Petros Pharmaceuticals guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Petros Pharmaceuticals. If investors know Petros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Petros Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (83.50) | Revenue Per Share | Quarterly Revenue Growth (0.06) | Return On Assets | Return On Equity |
The market value of Petros Pharmaceuticals is measured differently than its book value, which is the value of Petros that is recorded on the company's balance sheet. Investors also form their own opinion of Petros Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Petros Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Petros Pharmaceuticals' market value can be influenced by many factors that don't directly affect Petros Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Petros Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Petros Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Petros Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.